The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Open accessAbstract
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activators of transcription (STATs). Inhibition of JAKs can simultaneously block the function of multiple cytokines. Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatology can either be used systemically as oral drugs or locally in topical formulations. Inhibition of JAKs has been shown to be effective in various skin disorders. The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis. Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-versus-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo. Here, we aim to discuss the immunological basis and current stage of development of JAKi in dermatology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,596
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
A Road Map for Those Who Don't Know JAK-STAT
Aaronson, D. S., & Horvath, C. M. (2002) · Science · doi:10.1126/science.1071545 · Cited by 1,337
New insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Self-citation
Cited by
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Current Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
Metadata
- Authors
- Solimani, F., Meier, K., & Ghoreschi, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-03
- Volume
- 10
- Pages
- 2847-2847
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2990076552
- Cited by
- 308
- References
- 219
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Topical and Systemic JAK Inhibitors in Dermatology. https://app.cochat.ai/papers/10.3389/fimmu.2019.02847
- The paper
- Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging Topical and Systemic JAK Inhibitors in Dermatology. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
